362. Deputy Thomas P. Broughan asked the Minister for Health further to Parliamentary Question Nos. 238 and 670 of 18 October 2018, the reason the rare diseases technology review committee does not have a direct input into the NCPE health technology assessment process; if the committee will be permitted to replicate to the Scottish PACE model to have a direct input into the pharmacoeconomic evaluation of orphan medicinal products; and if he will make a statement on the matter. [47768/18]

Summary

362. Deputy Thomas P. Broughan asked the Minister for Health further to Parliamentary Question Nos. 238 and 670 of 18 October 2018, the reason the rare diseases technology review committee does not have a direct input into the NCPE health technology assessment process; if the committee will be permitted to replicate to the Scottish PACE model to have a direct input into the pharmacoeconomic evaluation of orphan medicinal products; and if he will make a statement on the matter. [47768/18]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products Prices

  xml · EN · 20 November 2018

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.